Principles of neoadjuvant therapy;Prinzipien der neoadjuvanten Therapie

Chirurg

Volumn 80, Issue 11, 2009, Pages 1000-1005

  Lordick, F ^a  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

Chemotherapy; Esophageal cancer; Gastric cancer; Neoadjuvant; Radiation therapy

Indexed keywords

ADENOCARCINOMA; ADJUVANT THERAPY; ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; GASTRECTOMY; HUMAN; LYMPH NODE METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; GASTRECTOMY; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 70449530774     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-009-1731-y     Document Type: Article

References (36)

1. Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7): 1521-1530.
2. Bedenne L, Michel P, Bouché O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25(10): 1160-1168.
3. Boige V, Pignon JP, Saint-Aubert B et al (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25(18): 4510 (Abstr).
4. Brücher BL, Becker K, Lordick F et al (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106(10): 2119-2127.
5. Cunningham D, Allum WH, Stenning SP et al (2006) MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1): 11-20.
6. Feussner H, Härtl F (2006) Staging laparoscopy in oncology. Chirurg 77(11): 971-980.
7. Fiorica F, Di Bona D, Schepis F et al (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53(7): 925-930.
8. Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8(3): 226-234.
9. Heidecke CD, Weighardt H, Feith M et al (2002) Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy. Surgery 132(3): 495-501.
10. Jouve J, Michel P, Mariette C et al (2008) Fédération Francophone de Cancérologie Digestive. Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. J Clin Oncol 26 [Suppl]: 4555 (Abstr).
11. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14): 2137-2150.
12. Lordick F (2005) Neoadjuvant therapy for squamous cell carcinoma of the esophagus. Chirurg 76: 1025-1032.
13. Lordick F, Jäger D (2008) Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointest Cancer Res 2(4): 187-197.
14. Lordick F, Lorenzen S, Hegewisch-Becker S et al (2007) Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI group. J Clin Oncol 25(18): 4514 (Abstr).
15. Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9): 797-805.
16. Lordick F, Ott K, Novotny A et al (2007) R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences. Chirurg 78(9): 792-801.
17. Lordick F, Ott K, Weitz J, Jäger D (2008) The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther 8(9): 1407-1415.
18. Lordick F, Ruers T, Aust DE et al (2008) Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 44(13): 1807-1819.
19. Lordick F, Stein HJ, Peschel C, Siewert JR (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91(5): 540-551.
20. Lorenzen S, Schuster T, Porschen R et al (2009) Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol (in press).
21. Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11): 2680-2686.
22. Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8(6): 545-553.
23. Meining A, Dittler HJ, Wolf A et al (2002) You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 50(5): 599-603.
24. Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21(24): 4604-4610.
25. Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29): 4692-4698.
26. Ribi K, Koeberle D, Schuller JC et al (2009) Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer (in press).
27. Schuhmacher CP, Fink U, Becker K et al (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91(5): 918-927.
28. Schuhmacher C, Schlag P, Lordick F et al (2009) Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol 27(15): 4510 (Abstr).
29. Shah MA, Ramanathan RK, Ilson DH et al (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(33): 5201-5206.
30. Siewert JR, Lordick F (2006) Response prediction - early response evaluation. Consequences for surgical oncology. Chirurg 77(12): 1095-1103.
31. Stahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30(2): 288-295.
32. Stahl M, Wilke H, Stuschke M et al (2005) Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 131(1): 67-72.
33. van Cutsem E, Kang Y, Chung H et al (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27 (15): 4509 (Abstr).
34. Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12): 3058-3065.
35. Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46: 2029-2034.
36. Wilke H, Preusser P, Fink U et al (1991) New developments in the treatment of gastric carcinoma. Cancer Treat Res 55: 363-373.